Access Pharmaceuticals Inc. develops and commercializes proprietary products for the treatment and care of cancer patients. The company today announced an agreement with commercial manufacturer Accupac Inc. to produce and distribute Access’ FDA-approved MuGard in the North American market.

MuGard is a mucoadhesive oral wound rinse for patients in radiation and chemotherapy that often-time develop mucositis, or the inflammation of mucous membranes along the lining of the digestive track, including the mouth. The company says the market for treating oral mucositis is estimated at $5 billion worldwide.

“Access is moving forward with the development of MuGard in North America,” Jeffrey B. Davis, Access’ president and CEO stated in the press release. “Establishing our relationship with Accupac, a leader in liquid contract manufacturing, is critical to our successful commercialization of MuGard. In addition, Access is currently evaluating potential eMarketing partners as well as potential co-promotion or other licensing opportunities.”

According to Access,

Access Pharmaceuticals, Inc.

(OTC:ACCP)

Many investors have raised concerns with regards to Access Pharmaceuticals being on the OTC. Indeed more than half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate investor demand. They will reach out to stock promoters, make deals with various PR companies and even go as far as releasing their own false press releases — usually involving buyouts (see OTC:PGYC). Folks, you need not worry, Access Pharma takes part in none of these illegal activities in order to induce demand, rather they focus on a solid and sound business strategy which willslowly take them into the promise land. Patience is a virtue.

MuGard is an interesting product with a lot of potential, and we truly believe that it

Since I last wrote about Access Pharma [ACCP: 0.00, N/A (N/A)] two weeks ago as a cancer biotech call option trade, the Company has issued two updates on its clinical development pipeline and two updates for MuGard – which is an oral rinse product for the management of a common side effect of many cancer therapies, mucositis. In late May, Access announced that MuGard was launched in Germany, Italy, UK, Greece, and the Nordic countries by its European commercial partner, SpePharm, with expected launches in North America, Asia, and other regions slated for later this year. On 6/10/09, ACCP.OB also announced that the Company received issue notifications from the United States Patent and Trademark Office for two US patents (numbers 7,544,348 and 7,547,433).

A video presentation is available at ProActiveNewsRoom.com for MuGard, in addition to more information and links at the landing page

Access Pharmaceuticals Inc., an emerging biopharmaceutical company, is focused on developing novel nanopolymer delivery technologies and products for cancer and dermatology. Currently, the company has one approved product, one product in phase 3 clinical development, four products in phase 2, and six products in preclinical development.

Although Access’ primary focus is on oncology and supportive care of cancer patients, the company has acquired product candidates in the dermatology field as well as additional oncology assets. The business development team is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for the company’s oncology and dermatology products, as well as nanopolymer technologies.

In most recent news, Access announced that it has received issue notifications from the United States Patent and Trademark Office that two US patents relating to MuGard TM , the company’s approved oral rinse product for the management of mucositis, will issue this month. MuGard is a ready-to-use

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.

Allos Therapeutics [ALTH: 7.19, -0.13 (-1.78%)]: On 5/30/09 , ALTH updated data from the Company’s pivotal Phase 2 PROPEL study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The overall response rate for pralatrexate as evaluated by central independent

The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson [JNJ: 55.50, +0.34 (+0.62%)] announcing a $1B cash tender offer for Cougar Biotech [CGRB: 42.87, -0.12 (-0.28%)] last week and Roche’s [ROG: 17.67, +0.61 (+3.58%)] [RHHBY: 0.00, N/A (N/A)] mega-deal to acquire full control of Genentech earlier this year. In addition, positive clinical trial results for Dendreon’s [DNDN: 23.2099, +0.5399 (+2.38%)] Provenge and stock price turnarounds from the brink of zero at Cell Therapeutics [CTIC: 1.60, +0.17 (+11.89%)] have fueled interest in the small and micro-cap cancer bio-pharma space among investors and traders looking for the next big trade.

Access Pharma [ACCP: 0.00, N/A (N/A)] is an emerging bio-pharma company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.

The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.

Theravance [THRX: 14.54, 0.00 (0.00%)]: On 4/24/09, the FDA accepted as complete for review Theravance’s response to the February 2009 Complete Response Letter (CRL), which outlined requirements for approval of telavancin for the treatment of complicated skin and skin structure infections (cSSSI). Telavancin is

Medivisor Inc. is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Headquartered in Huntington Station, New York, the Company exclusively serves the bioscience and pharmaceutical markets. They offer specialized medical marketing consulting, graphic design, web site marketing strategy, and market research.

Medivisor provides concise and timely medical information through the internet on advances in medicine and changes within the industry. They also utilize sales representatives who make periodic visits to healthcare providers. The Company’s business model provides a cost effective, efficient way to make medical personnel aware of opportunities, tools, information, and resources available to them as part of their patient care. Medivisor also collaborates with pharmaceutical distribution companies to market and grow sales of new and current drugs. This aids in lowering current marketing costs and helps to bring products and services to market.

Medivisor reached an exclusive marketing and distribution agreement with